Loading company
Evommune, Inc.
EVMN · NYSE · ·
$8.33-0.7%Sep 29 close
- 1M
- -37.0%
- 6M
- -62.1%
EVMN · NYSE · ·
$8.33-0.7%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$32.2M | -$13.6M | -137.71% |
| Profit per share | -$0.89 | -$8.80 | +89.89% |
| Free Cash Flow | -$20.5M | -$26.2M | +21.78% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Evommune, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Evommune, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.